<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503776</url>
  </required_header>
  <id_info>
    <org_study_id>VICC HN 0554</org_study_id>
    <secondary_id>VU-VICC-HN-0554</secondary_id>
    <secondary_id>VU-VICC-IRB-051068</secondary_id>
    <nct_id>NCT00503776</nct_id>
  </id_info>
  <brief_title>Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, &amp; Dysphagia</brief_title>
  <official_title>Randomized Pilot Trial of Chemoradiation Plus or Minus Amifostine to Assess Potential Nutritional, Inflammatory and Physical Outcomes Related to Xerostomia, Mucositis and Dysphagia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses
      high-energy x-rays to kill tumor cells. Amifostine may decrease the side effects caused by
      chemotherapy and radiation therapy. It is not yet known whether chemotherapy and radiation
      therapy are more effective with or without amifostine in treating head and neck cancer.

      PURPOSE: This randomized phase II trial is studying amifostine to see how well it works
      compared with standard care in reducing side effects in patients undergoing chemotherapy and
      radiation therapy for stage III or stage IV head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the incidence and severity of acute and chronic swallowing dysfunction in
           stage III or IV head and neck cancer patients receiving concurrent chemoradiation with
           or without amifostine

      Secondary

        -  To assess the relative incidence and severity of acute and chronic xerostomia in stage
           III or IV head and neck cancer patients receiving chemoradiation with or without
           amifostine.

        -  To assess the relative incidence and severity of mucositis and mucositis-related
           inflammation in stage III or IV head and neck cancer patients receiving chemoradiation
           with or without amifostine.

        -  To assess the effects of dysphagia, xerostomia, and mucositis-related inflammation on
           nutritional, physical, and functional status

      OUTLINE: Patients undergo intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy
      comprising carboplatin and paclitaxel weekly.

      Patients are randomized to 1 of 2 treatment arms.

        -  Arm I (standard of care): Patients are further divided into 1A or 1B.

             -  Arm IA: Standard of care plus standardized nutrition therapy (SNT)

             -  Arm IB: Standard of care plus standardized nutrition therapy plus low weight
                resistance training (LWRT).

        -  Arm II (amifostine): Patients are further divided into 2A or 2B.

             -  Arm IIA: Amifostine 500mg diluted in 2.9 ml injected 30-60 minutes prior to each
                radiation dose plus standardized nutrition therapy

             -  Arm IIB: Amifostine 500mg diluted in 2.9 ml injected 30-60 minutes prior to each
                radiation dose plus standardized nutrition therapy plus low weight resistance
                training

      In all arms, patients undergo swallowing function, dietary, body composition, muscle, and
      physical and functional performance measurements at baseline and at 1, 3, and 6 months
      post-therapy. Quality of life, salivary production, fatigue, and symptoms (including
      swallowing/eating foods, appetite, weight loss/nutrition, pain, and speech/communication) are
      assessed at baseline and at 1, 3, and 6 months post-therapy. Anthropometric measurements are
      also performed at the above time points and at mid-therapy.

      Blood samples and buccal rinses are collected at baseline and at 1, 3, and 6 months
      post-therapy for biomarker studies and for proteomic and genomic analysis by liquid
      chromatography and tandem mass spectrometry.

      After completion of study treatment, patients are followed at 1, 3, and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding became unavailable
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Each Degree of Swallowing Dysfunction</measure>
    <time_frame>6 months after concurrent chemotherapy and radiation</time_frame>
    <description>Grade of swallowing dysfunction as measured by the modified barium swallow score: grade 1, normal; grade 2, within functional limits; grade 3, mild impairment; grade 4, mild to moderate impairment; grade 5, moderate impairment; grade 6, moderate to severe impairment; grade 7, severe impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stimulated and Unstimulated Salivary Production</measure>
    <time_frame>6 months after concurrent chemotherapy and radiation</time_frame>
    <description>Unstimulated and stimulated salivary production, measured in mL/minute. Unstimulated salivary production is determined by expectoration of passively accumulated secretions accumulated in three 2-minute periods. Stimulated salivary production is determined by chewing paraffin wax with expectoration of passively accumulated secretions accumulated in three 2-minute periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Oral Mucositis by Grade</measure>
    <time_frame>6 months after concurrent chemotherapy and radiation</time_frame>
    <description>Measured by Common Toxicity Criteria (CTC) v. 3.00 = no mucositis (minimum score), 1 = mild mucositis, 2 = moderate mucositis, 3 = severe mucositis, 4 = life-threatening, disabling mucositis, 5 = death (worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Amount and Texture of Food Consumed</measure>
    <time_frame>at baseline, at 1 month, 3 months and 6 months post-chemoradiation</time_frame>
    <description>Patients are asked to note their food intake in terms of amount and texture over the past 24 hours as measured by 24-hour dietary recalls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Frequency and Types of Dietary Intakes</measure>
    <time_frame>at baseline, at 1 month, 3 months and 6 months post-chemoradiation</time_frame>
    <description>Patients are asked to note their food intake in terms of amount and texture over the past 24 hours as measured by 24 hour dietary recalls.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Dysphagia</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Mucositis</condition>
  <condition>Xerostomia</condition>
  <arm_group>
    <arm_group_label>Arm IA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo SNT and low weight resistance training (LWRT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise intervention</intervention_name>
    <description>Patients undergo low weight resistance training.</description>
    <arm_group_label>Arm IB</arm_group_label>
    <arm_group_label>Arm IIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm IIA</arm_group_label>
    <arm_group_label>Arm IIB</arm_group_label>
    <other_name>Ethyol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic dietary intervention</intervention_name>
    <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
    <arm_group_label>Arm IA</arm_group_label>
    <arm_group_label>Arm IB</arm_group_label>
    <arm_group_label>Arm IIA</arm_group_label>
    <arm_group_label>Arm IIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age greater than 21

          -  Biopsy proven stage 3 or 4 squamous cell carcinoma of the larynx, pharynx, oral cavity
             or salivary glands

          -  No prior history of active cancer within three years other than non-melanoma skin
             cancer, early stage prostate or early stage cervical cancer

          -  controlled co-morbid disease

          -  ECOG PS of 0-3

          -  Plan for definitive or post-operative CCR within 4 weeks

          -  Written informed consent

          -  Working telephone

          -  May have received prior induction chemotherapy

          -  Agree to use only study supplied liquid nutrition supplements or dietary supplements,
             for per os or feeding tube intake

        Exclusion Criteria

          -  Diagnosed HIV or AIDS

          -  History of ETOH or drug abuse within 3 months

          -  Pregnant or lactating

          -  On steroid medication or prescribed NSAIDs

          -  Consuming specialty nutrition supplements containing additional amounts of
             eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA)

          -  On orexigenic (appetite stimulant) medication.

          -  Uncontrolled comorbid disease defined as: a) severe cardiac disease Class III or
             greater; b) blood pressure &gt; 160/95; c) uncontrolled pain

          -  Does not have working telephone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara A. Murphy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <results_first_submitted>November 3, 2011</results_first_submitted>
  <results_first_submitted_qc>November 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2011</results_first_posted>
  <last_update_submitted>May 28, 2017</last_update_submitted>
  <last_update_submitted_qc>May 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Barbara Murphy, MD</investigator_full_name>
    <investigator_title>Professor of Medicine; Director, Cancer Supportive Care Program; Director, Head and Neck Research Program; Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>xerostomia</keyword>
  <keyword>mucositis</keyword>
  <keyword>dysphagia</keyword>
  <keyword>radiation toxicity</keyword>
  <keyword>chemotherapeutic agent toxicity</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Deglutition Disorders</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was open to accrual from 01/01/2006 through 03/05/2008.</recruitment_details>
      <pre_assignment_details>43 patients consented, one was ineligible for a total of 42 patients on study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm IA</title>
          <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
        </group>
        <group group_id="P2">
          <title>Arm IB</title>
          <description>Patients undergo SNT and low weight resistance training (LWRT).</description>
        </group>
        <group group_id="P3">
          <title>Arm IIA</title>
          <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.</description>
        </group>
        <group group_id="P4">
          <title>Arm IIB</title>
          <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12">one patient withdrew before receiving protocol therapy</participants>
                <participants group_id="P4" count="10">one patient withdrew before receiving protocol therapy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm IA</title>
          <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
        </group>
        <group group_id="B2">
          <title>Arm IB</title>
          <description>Patients undergo SNT and low weight resistance training (LWRT).</description>
        </group>
        <group group_id="B3">
          <title>Arm IIA</title>
          <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.</description>
        </group>
        <group group_id="B4">
          <title>Arm IIB</title>
          <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="1"/>
                    <measurement group_id="B2" value="55" spread="1"/>
                    <measurement group_id="B3" value="54" spread="1"/>
                    <measurement group_id="B4" value="55" spread="1"/>
                    <measurement group_id="B5" value="54" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Each Degree of Swallowing Dysfunction</title>
        <description>Grade of swallowing dysfunction as measured by the modified barium swallow score: grade 1, normal; grade 2, within functional limits; grade 3, mild impairment; grade 4, mild to moderate impairment; grade 5, moderate impairment; grade 6, moderate to severe impairment; grade 7, severe impairment</description>
        <time_frame>6 months after concurrent chemotherapy and radiation</time_frame>
        <population>One patient (Arm 2B) did not undergo the 6-month study</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IA</title>
            <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O2">
            <title>Arm IB</title>
            <description>Patients undergo SNT and low-weight resistance training (LWRT).</description>
          </group>
          <group group_id="O3">
            <title>Arm IIA</title>
            <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.</description>
          </group>
          <group group_id="O4">
            <title>Arm IIB</title>
            <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Each Degree of Swallowing Dysfunction</title>
          <description>Grade of swallowing dysfunction as measured by the modified barium swallow score: grade 1, normal; grade 2, within functional limits; grade 3, mild impairment; grade 4, mild to moderate impairment; grade 5, moderate impairment; grade 6, moderate to severe impairment; grade 7, severe impairment</description>
          <population>One patient (Arm 2B) did not undergo the 6-month study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. of patients with dysphagia grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with dysphagia grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with dysphagia grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with dysphagia grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with dysphagia grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Accessible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stimulated and Unstimulated Salivary Production</title>
        <description>Unstimulated and stimulated salivary production, measured in mL/minute. Unstimulated salivary production is determined by expectoration of passively accumulated secretions accumulated in three 2-minute periods. Stimulated salivary production is determined by chewing paraffin wax with expectoration of passively accumulated secretions accumulated in three 2-minute periods.</description>
        <time_frame>6 months after concurrent chemotherapy and radiation</time_frame>
        <population>Patients who underwent salivary testing at 6 months. The following patients were not available at 6- months for testing for salivary production: Arm 1A (1), Arm 1B (4), Arm 2A (3), Arm 2B (2)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IA</title>
            <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O2">
            <title>Arm IB</title>
            <description>Patients undergo SNT and low weight resistance training (LWRT).</description>
          </group>
          <group group_id="O3">
            <title>Arm IIA</title>
            <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.</description>
          </group>
          <group group_id="O4">
            <title>Arm IIB</title>
            <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.</description>
          </group>
        </group_list>
        <measure>
          <title>Stimulated and Unstimulated Salivary Production</title>
          <description>Unstimulated and stimulated salivary production, measured in mL/minute. Unstimulated salivary production is determined by expectoration of passively accumulated secretions accumulated in three 2-minute periods. Stimulated salivary production is determined by chewing paraffin wax with expectoration of passively accumulated secretions accumulated in three 2-minute periods.</description>
          <population>Patients who underwent salivary testing at 6 months. The following patients were not available at 6- months for testing for salivary production: Arm 1A (1), Arm 1B (4), Arm 2A (3), Arm 2B (2)</population>
          <units>mL per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unstimulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.37"/>
                    <measurement group_id="O2" value="1.70" spread="1.44"/>
                    <measurement group_id="O3" value="1.38" spread="1.90"/>
                    <measurement group_id="O4" value="0.68" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stimulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.85"/>
                    <measurement group_id="O2" value="5.04" spread="3.16"/>
                    <measurement group_id="O3" value="5.25" spread="3.39"/>
                    <measurement group_id="O4" value="0.94" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Oral Mucositis by Grade</title>
        <description>Measured by Common Toxicity Criteria (CTC) v. 3.00 = no mucositis (minimum score), 1 = mild mucositis, 2 = moderate mucositis, 3 = severe mucositis, 4 = life-threatening, disabling mucositis, 5 = death (worst score).</description>
        <time_frame>6 months after concurrent chemotherapy and radiation</time_frame>
        <population>Participants available for 6-month follow-up oral examination. No 6-month follow-up data were available for the following numbers of patients: Arm 1A (1), Arm 1B (4), Arm 2A (3), Arm 2B (2).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IA</title>
            <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O2">
            <title>Arm IB</title>
            <description>Patients undergo SNT and low weight resistance training (LWRT).</description>
          </group>
          <group group_id="O3">
            <title>Arm IIA</title>
            <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.</description>
          </group>
          <group group_id="O4">
            <title>Arm IIB</title>
            <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Oral Mucositis by Grade</title>
          <description>Measured by Common Toxicity Criteria (CTC) v. 3.00 = no mucositis (minimum score), 1 = mild mucositis, 2 = moderate mucositis, 3 = severe mucositis, 4 = life-threatening, disabling mucositis, 5 = death (worst score).</description>
          <population>Participants available for 6-month follow-up oral examination. No 6-month follow-up data were available for the following numbers of patients: Arm 1A (1), Arm 1B (4), Arm 2A (3), Arm 2B (2).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. of patients with grade 0, no mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with grade 1, mild mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No of patients with grade 2, moderate mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No of patients with grade 3, severe mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with grade 4, disabling mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with grade 5 mucositis, death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Amount and Texture of Food Consumed</title>
        <description>Patients are asked to note their food intake in terms of amount and texture over the past 24 hours as measured by 24-hour dietary recalls.</description>
        <time_frame>at baseline, at 1 month, 3 months and 6 months post-chemoradiation</time_frame>
        <population>Due to loss of funding, sufficient data for analysis was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IA</title>
            <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
therapeutic dietary intervention: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O2">
            <title>Arm IB</title>
            <description>Patients undergo SNT and low weight resistance training (LWRT).
exercise intervention: Patients undergo low weight resistance training.
therapeutic dietary intervention: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O3">
            <title>Arm IIA</title>
            <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
amifostine trihydrate: Given subcutaneously
therapeutic dietary intervention: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O4">
            <title>Arm IIB</title>
            <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
exercise intervention: Patients undergo low weight resistance training.
amifostine trihydrate: Given subcutaneously
therapeutic dietary intervention: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Amount and Texture of Food Consumed</title>
          <description>Patients are asked to note their food intake in terms of amount and texture over the past 24 hours as measured by 24-hour dietary recalls.</description>
          <population>Due to loss of funding, sufficient data for analysis was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Frequency and Types of Dietary Intakes</title>
        <description>Patients are asked to note their food intake in terms of amount and texture over the past 24 hours as measured by 24 hour dietary recalls.</description>
        <time_frame>at baseline, at 1 month, 3 months and 6 months post-chemoradiation</time_frame>
        <population>Due to loss of funding, sufficient data for analysis was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IA</title>
            <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
therapeutic dietary intervention: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O2">
            <title>Arm IB</title>
            <description>Patients undergo SNT and low weight resistance training (LWRT).
exercise intervention: Patients undergo low weight resistance training.
therapeutic dietary intervention: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O3">
            <title>Arm IIA</title>
            <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
amifostine trihydrate: Given subcutaneously
therapeutic dietary intervention: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
          <group group_id="O4">
            <title>Arm IIB</title>
            <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
exercise intervention: Patients undergo low weight resistance training.
amifostine trihydrate: Given subcutaneously
therapeutic dietary intervention: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Frequency and Types of Dietary Intakes</title>
          <description>Patients are asked to note their food intake in terms of amount and texture over the past 24 hours as measured by 24 hour dietary recalls.</description>
          <population>Due to loss of funding, sufficient data for analysis was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm IA</title>
          <description>Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.</description>
        </group>
        <group group_id="E2">
          <title>Arm IB</title>
          <description>Patients undergo SNT and low weight resistance training (LWRT).</description>
        </group>
        <group group_id="E3">
          <title>Arm IIA</title>
          <description>Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.</description>
        </group>
        <group group_id="E4">
          <title>Arm IIB</title>
          <description>Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>accute hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>mucositis/stomatitis-oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - abdomen NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>pain - oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>pain - rectal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain - larynx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>pain - NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever-in absence of neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rigor, chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>edema limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils-blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness - lower extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>rash/desquamation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="22" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="23" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E3" events="24" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E4" events="14" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>difficulty chewing</sub_title>
                <counts group_id="E1" events="17" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="30" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E3" events="29" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E4" events="23" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="46" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" events="42" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" events="34" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="40" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" events="33" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E4" events="32" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" events="17" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E4" events="15" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="32" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="46" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" events="40" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" events="31" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Murphy, MD</name_or_title>
      <organization>Vanderbilt-Ingram Cancer Center</organization>
      <phone>615-343-9444</phone>
      <email>barbara.murphy@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

